Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

of Days 2-5, and during the overall period of Days 1-5. On Day 1, 100% of patients had no emesis and at least 95% of patients had no emetic episodes in the delayed and overall time periods. A complete response was demonstrated in 75% of patients on Day 1 and in 67% of patients in the delayed time period. Based on VAS, the majority of patients had no significant nausea in the acute, delayed or overall phases. The most commonly observed adverse events were headache and fatigue.

Phase 3 Results of Aloxi in Pediatric Patients

The results of a phase 3, multicenter, randomized, double-blind study to assess the safety, efficacy and pharmacokinetics of single intravenous doses of Aloxi in pediatric patients were presented in a poster session on Sunday, June 3, 2007. Sixty patients (2-17 years of age) were randomized to receive either 3 mcg/kg or 10 mcg/kg with a maximum total dose of 0.25 mg and 0.75mg, respectively, prior to moderately (n=21) or highly (n=39) emetogenic chemotherapy. Twelve additional patients, age 28 days-23 months, were studied in open-label design at the same doses. The majority of patients had received previous chemotherapy. Day 1 complete response (CR: no emetic episodes and no rescue medication) rates of 37.1% (CI, 22.0-55.1%) and 54.1% (CI, 37.1-70.2%) were reported in the 3 mcg/kg (n=35) and 10 mcg/kg (n=37) groups, respectively. The percentage of patients who were emesis-free was numerically higher in the 10 mcg/kg group; however, as with CR, these differences were primarily seen in children less than 2 years. A numerically higher proportion of patients (aged 6-17 years) with no nausea was also observed in the 10 mcg/kg group. Both doses showed a similar time to treatment failure (time to first emetic episode and/or first administration of rescue medication). The pharmacokinetic data show that total body clearance and volume of distribution of Aloxi increased with age-related body weight, as expected. The long half-life (21-37 hours
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: ... first quarter financial results on Tuesday, April 21, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
(Date:4/16/2015)... 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) announced ... with a newly formed specialty healthcare company focused ... addressing urological disorders. The merged company, which is ... commenced operations and incorporates the pipeline assets of ... strategy is to build a late-stage and commercial ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... April 18, 2015 Carinsurancehints.com has released a ... plans that offer financial protection against fire damage. ... pay benefits in case their vehicle is set intentionally on ... caused by rioting or by other things. , It ... on a single website http://www.carinsurancehints.com/ , in just ...
(Date:4/18/2015)... PITTSBURGH, PA (PRWEB) April 18, 2015 ... so I decided to create a healthful juice ... an inventor from Rosedale, Md. "It increases my ... overall healthy body." , He developed Tapp's Juice ... The juice helps to prevent physical and mental ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post explaining ... , Clients can review important auto insurance quotes ... provides important advantages for clients who need affordable financial ... not have coverage for their vehicles can purchase a ... hour. Many agencies offer important discounts and drivers can ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... BATESVILLE, Ind., Feb. 8 Hillenbrand,Industries, Inc. (NYSE: ... of $0.285 per share. This dividend was declared by ... payable on March 31, 2008 to,shareholders of record at ... ABOUT HILLENBRAND INDUSTRIES, INC., Hillenbrand Industries is organized ...
... sees greater activation of key brain region than found in ... a video game "widow," science might now be able to ... shows that the part of the brain associated with reward ... when both genders played a game whose object was to ...
... 3 Program of CGT-2168, MENLO PARK, ... named a distinguished international panel of medical ... charged with overseeing COGENT,the company,s global Phase ... antiplatelet product CGT-2168., (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ...
... happy and healthy ... control, WESTPORT, Conn., Feb. 8 Just in ... diabetes information,inspiration, and connection, has a spicy and informative ... people with diabetes.,Accessible at http://www.dlife.com/diabetes-valentines, the quiz ...
... sales of $20.4 million versus $24.1 ... million in the same quarter last year., - ... initial shipments expected during the second half of fiscal 2008., ... ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer and marketer ...
... Stereotaxis, Inc. (Nasdaq:,STXS), announced today that Bevil ... Chief Financial Officer, will present at the Deutsche ... Carlton Hotel in Naples,Florida on Thursday, February 14, ... at the conference is by invitation only. The ...
Cached Medicine News:Health News:For Males, Video Game Rewards Are All in the Mind 2Health News:For Males, Video Game Rewards Are All in the Mind 3Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 2Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 3Health News:Love and Diabetes: dLife Valentine's Day Quiz Tests and Teaches Important Relationship Lessons for People With Diabetes 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 3Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 4Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 5
Soft silicone brush tip allows atraumatic brushing and manipulation of retina surface. Silicone brush extends 3mm beyond end of cannula. Luer lock hub for easy, secure connection to a backflush handl...
Maumenee vitreous aspirating cannula, 18 gauge....
Reusable cannula with .90 mm (20 g) shaft, tapering to .60 mm (23 g) 3 mm from the tip. Overall length is 29 mm....
... silicone tip cannula allows atraumatic ... hole for aspiration of subretinal ... 6mm beyond end of cannula. ... easy, secure connection to a ...
Medicine Products: